Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Drug Testing

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

CDT helps employers ensure reliable, accurate and confidential drug testing tailored to meet your needs. Our services include administrative support, collections, random pool selection, analysis, medical review and reporting of results, utilizing flexible web-based solutions.
Drug Policy Development

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

A strong drug testing policy is the foundation of an effective program. Detailed policy consulting and development are our strengths. As a pioneer in the field, our experts are knowledgeable on state and federal laws that govern the employment screening process.
Training & Education Programs

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

The power of bringing in an expert to talk with employees, supervisors or other key groups cannot be underestimated. In addition, CDT provides interactive on line training and education programs. Our online reasonable suspicion supervisor training meets the DOT requirements.
Recent News & Policy Developments

FMCSA Proposes National Drug and Alcohol Testing Clearinghouse for Commercial Truck and Bus Drivers 02-12-2014
WASHINGTON - The U.S. Department of Transportation's Federal Motor Carrier Safety Administration (FMCSA) today announced a proposed rule to establish a drug and alcohol clearinghouse for all national commercial driver's license (CDL) holders. The clearinghouse would help improve roadway safety by making it easier to determine whether a truck or bus driver is prohibited from operating a commercial motor vehicle for failing to comply with federal drug and alcohol regulations, including mandatory testing.

Emerging Regulations – Prescription Drugs and Oral Fluid 02-08-2012
Last month, the Substance Abuse and Mental Health Services Administration (SAMHSA) announced that it accepted the recommendations of its Drug Testing Advisory Board (DTAB), and will proceed with drafting revisions to the DHHS Mandatory Guidelines for Federal Workplace Drug Testing Programs. The changes would include:
  1. Expanding the drug testing panel to include additional Schedule II prescription medications (e.g., oxycodone, oxymorphone, hydrocodone and hydromorphone).
  2. Including oral fluid as an alternative specimen for Federal Drug Free Workplace testing.
Click here to review the full article.

Hydrocodone and Oxycodones Lead U.S. General Workforce Positives 10-11-2011
American workers continue to use prescription opiates at relatively high levels, according to Drug Testing Index™ (DTI) data released today by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. Hydrocodone and oxycodones remain the most detected prescription opiates in the U.S. general workforce, with 1.3% and 1.1% positivity rates, respectively, in the first half of 2011. Compared to 2005 levels, oxycodones are 96% higher (0.56% vs. 1.1%) and hydrocodone 47% higher (0.88% vs. 1.3%) in positive prevalence.

DOT Extends The Use Of Old Chain of Custody Forms Until November 30th, 2011 09-27-2011
Among amendments to the Interim ruling; employers that fall under the DOT drug testing regulations, 49 CFR Part 40, can continue to use old CCF forms until November 30, 2011. This extension will provide the DOT and employers more time to implement the use of the new forms. We have done an illustration in order to identify the new COC forms here.

Quest Diagnostics Issued Its Annual Drug Testing Index Report 09-12-2011
The study includes its first state-by-state analysis of methamphetamine positives, based on more than 4.5 million urine specimens collected from the general U.S. workforce from January-December 2010, revealing that several Western and Midwestern states register dramatically higher workforce positive prevalence rates for methamphetamine than the national average. The report also shows that while efforts around the country to control availability of the highly addictive substance and educate against its use may be making progress in some areas, the drug's attraction among U.S. workers may be moving eastward.

DEA Moves to Emergency Control Synthetic Stimulants (Bath Salts) 09-07-2011
The United States Drug Enforcement Administration (DEA) is using its emergency scheduling authority to temporarily control three synthetic stimulants (Mephedrone , 3,4 methylenedioxypyrovalerone (MDPV) and Methylone). This action was necessary to protect the public from the imminent hazard posed by these dangerous chemicals. Except as authorized by law, this action will make possessing and selling these chemicals or the products that contain them illegal in the U.S. for at least one year while the DEA and the United States Department of Health and Human Services (DHHS) further study whether these chemicals should be permanently controlled.
READ MORE

"Bath Salt" Abuse is a Growing Menace 01-31-2011
The MEDTOX Drug Abuse Recognition (DAR) Hotline has been peppered with calls about ingestion and abuse of bath salts over the last several months. The first Hotline calls were fielded in June of 2010; volume hit a peak this month. Abuse of bath salts and particular strains of powdered plant food has now been reported by a number of media outlets, as well as by state and federal law enforcement agencies. This activity is real and it represents a notable public safety threat. Readers should be sensitive to this substance abuse and be prepared for bad outcomes for some users. Our staff believes the problem warrants a special "be on the lookout" advisory for our readers.